Danh mục

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study

Số trang: 10      Loại file: pdf      Dung lượng: 1.33 MB      Lượt xem: 9      Lượt tải: 0    
Hoai.2512

Hỗ trợ phí lưu trữ khi tải xuống: 5,000 VND Tải xuống file đầy đủ (10 trang) 0
Xem trước 2 trang đầu tiên của tài liệu này:

Thông tin tài liệu:

Immunotherapy (IO) has become a standard of care for treating various types of metastatic cancers and has significantly improved clinical outcome. With the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months, these treatments are currently administered until either disease pro‑ gression for some IO, 2 years for others, or unacceptable toxicity.
Nội dung trích xuất từ tài liệu:
A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: The MOIO protocol study

Tài liệu được xem nhiều: